Notice to Correct an Application Review Date, and the Phased Activity Description of RFA-NS-16-013 "Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33)"

Notice Number: NOT-NS-16-001

Key Dates
Release Date:   December 2, 2015

Related Announcements
RFA-NS-16-013      

Issued by
National Institute of Neurological Disorders and Stroke (NINDS

Purpose

The purpose of this Notice is to correct a review date and the activity description section of NINDS RFA-NS-16-013 "Innovation Grants to Nurture Initial Translational Efforts (IGNITE):  Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33)".

Part 1. Overview Information

Key Dates

The FOA currently reads:

Scientific Merit Review
June 2016; October 2106; February 2017; June 2017; October 2107; February 2018   

The FOA is now changed to read:
Scientific Merit Review
June 2016; October 2016; February 2017; June 2017; October 2017; February 2018   

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

The FOA currently reads:

Activities in the R21 Phase

  • Initial development of the model, testing paradigm, ex vivo system or PD measure
  • Any optimization of the above related to feasibility, endpoint range and sensitivity, potential to scale up for validation studies (breeding, aging, etc.), specificity of the model system/PD measure as it relates to the disease or endpoint measures, identification of confounding variables, etc.
  • Activities in the R33 Phase Complete internal validation for endpoints used in the model system or PD measure
  • Scale-up for external validation studies
  • All external validation studies, including comparisons of phenotype to human disease, comparisons of disease etiology in preclinical species to what is known about the human disease and efficacy of clinically tested therapeutic agents (if available) in the new model system

The FOA is now changed to read:            
Activities in the R21 Phase:

  • Initial development of the model, testing paradigm, ex vivo system or PD measure
  • Any optimization of the above related to feasibility, endpoint range and sensitivity, potential to scale up for validation studies (breeding, aging, etc.), specificity of the model system/PD measure as it relates to the disease or endpoint measures, identification of confounding variables, etc.
Activities in the R33 Phase:
  • Complete internal validation for endpoints used in the model system or PD measure
  • Scale-up for external validation studies
  • All external validation studies, including comparisons of phenotype to human disease, comparisons of disease etiology in preclinical species to what is known about the human disease and efficacy of clinically tested therapeutic agents (if available) in the new model system

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Mary Ann Pelleymounter, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779
Email: mary.pelleymounter@mail.nih.gov